Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185035 | 0.84 | MAPT (0.46) | LMNAMAPTALDH1A1HTTMEN1 | |
| SCHEMBL2418954 | 0.82 | CHKA (0.56) | LMNAMAPTALDH1A1HTTMEN1 | |
| SCHEMBL4466850 | 0.80 | CHKA (0.54) | LMNAMAPTALDH1A1HTTMEN1 | |
| SCHEMBL49166 | 0.77 | CHKA (0.67) | LMNAMAPTALDH1A1HTTMEN1 | |
| SCHEMBL3540198 | 0.77 | PLD1 (0.60) | ALDH1A1HTTCYP1A2KDM4ETP53 | |
| SCHEMBL8925000 | 0.77 | HRH4 (0.46) | MAPTALDH1A1HTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8912436 | 0.75 | CHKA (0.64) | LMNAMAPTALDH1A1HTTMEN1 | |
| SCHEMBL9093746 | 0.73 | LMNA (0.71) | LMNAMAPTALDH1A1HTTMEN1 | |
| SCHEMBL1515215 | 0.72 | LMNA (0.47) | LMNAMAPTALDH1A1HTTMEN1 | |
| SCHEMBL1481690 | 0.72 | HRH3 (0.51) | LMNAMAPTALDH1A1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024056077-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-21 | — | — | WO | disclosed |
| CN-108699052-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10344056-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3397638-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Merial, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| CN-108699052-A | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | 梅里亚股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1115707-B1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344056-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | LMNA 2969/4885MAPT 4136/4885ALDH1A1 2890/4885 |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | LMNA 2297/4885MAPT 3676/4885ALDH1A1 2924/4885 |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | LMNA 2969/4885MAPT 4136/4885ALDH1A1 2890/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | LMNA 3826/4885MAPT 1548/4885ALDH1A1 1181/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | LMNA 3680/4885MAPT 859/4885ALDH1A1 2467/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | LMNA 2969/4885MAPT 4136/4885ALDH1A1 2890/4885 |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | LMNA 2969/4885MAPT 4136/4885ALDH1A1 2890/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | LMNA 2969/4885MAPT 4136/4885ALDH1A1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.